VistaGen Therapeutics appoints Maggie FitzPatrick to board, replacing retiring director Brian Underdown

Vistagen Therapeutics, Inc.

Dr. Brian J. Underdown retired from VistaGen's board and all committees, effective July 21, 2021, with no disagreement.
Maggie FitzPatrick appointed as independent director; she is a former chief corporate affairs officer at Exelon and J&J.
Mary L. Rotunno appointed Chair of Corporate Governance and Nominating Committee and member of Audit Committee.
Jerry B. Gin appointed Chair of Compensation Committee; FitzPatrick also named to Corporate Governance and Nominating Committee.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian J. Underdown

Director

VTGN · Vistagen Therapeutics, Inc.

Effective: 2021-07-21
Successor: Margaret M. FitzPatrick
Filed: July 22, 2021, 7:59 PM ET

Dr. Brian J. Underdown notified the Board of Directors (the “ Board ”) of VistaGen Therapeutics, Inc. (the “ Company ”) of his retirement from the Board and all Board committees, effective immediately.

Appointed

Margaret M. FitzPatrick

Director

VTGN · Vistagen Therapeutics, Inc.

Effective: 2021-07-21
Filed: July 22, 2021, 7:59 PM ET

the Board appointed Margaret M. FitzPatrick to serve on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian J. Underdown retired as Director at Vistagen Therapeutics, Inc..

Action: retired
Role: Director

Exact text from the filing

Dr. Brian J. Underdown notified the Board of Directors (the “ Board ”) of VistaGen Therapeutics, Inc. (the “ Company ”) of his retirement from the Board and all Board committees, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Margaret M. FitzPatrick was appointed as Director at Vistagen Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Margaret M. FitzPatrick to serve on the Board.

View on SEC.gov

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-21-008125

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.